W
ith new diagnoses in more than 480,000 patients annually, esophageal cancer is the eighth most common cancer worldwide. 1 It is a highly lethal disease, causing more than 400,000 deaths per year. 2 The incidence of esophageal adenocarcinoma is rapidly rising, whereas that of squamous-cell carcinoma remains unchanged. 3 Despite adequate preoperative staging, 25% of patients treated with primary surgery have microscopically positive resection margins (R1), and the 5-year survival rate rarely exceeds 40%. 4 The role of neoadjuvant chemoradiotherapy has been debated for several decades. In most randomized trials, no survival benefit could be shown, and the trials were criticized for inadequate trial design, samples that were too small, and poor outcomes in the surgery-alone group. Meta-analyses suggest a survival benefit from neoadjuvant chemoradiotherapy, albeit frequently at the cost of increased postoperative morbidity and mortality. 5, 6 We previously reported a phase 2 trial of neoadjuvant chemoradiotherapy consisting of weekly administration of carboplatin and paclitaxel with concurrent radiotherapy. 7 This regimen was associated with a low rate of serious toxic effects, and a complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in all patients who underwent resection. These results encouraged us to initiate a multicenter, randomized, controlled, phase 3 study comparing neoadjuvant chemoradiotherapy followed by surgery with surgery alone in patients with potentially curable esophageal or esophagogastricjunction carcinoma. 8 
ME THODS

ELIGIBILITY CRITERIA
Patients with histologically confirmed, potentially curable squamous-cell carcinoma, adenocarcinoma, or large-cell undifferentiated carcinoma of the esophagus or esophagogastric junction (i.e., tumors involving both the cardia and the esophagus on endoscopy) were eligible for inclusion in the study. The upper border of the tumor had to be at least 3 cm below the upper esophageal sphincter. Patients who had proximal gastric tumors with minimal invasion of the esophagus were excluded. The length and width of the tumor could not exceed 8 cm and 5 cm, respectively. Only patients with tumors of clinical stage T1N1 or T2-3N0-1 and no clinical evidence of metastatic spread (M0), according to the International Union against Cancer (UICC) tumor-node-metastasis (TNM) classification, 9 were enrolled. Eligible patients were 18 to 75 years of age, had a World Health Organization (WHO) performance status score of 2 or lower (on a scale of 0 to 5, with 0 indicating fully active, 1 unable to carry out heavy physical work, and 2 up and about more than half the day but unable to work), and had lost 10% or less of body weight. Patients also had to have adequate hematologic, renal, hepatic, and pulmonary function, as well as no history of other cancer or previous radiotherapy or chemotherapy.
All patients provided written informed consent. The institutional review board at each participating center approved the study protocol. 8 The protocol, including the statistical analysis plan, is available with the full text of this article at NEJM.org. No commercial support was involved in the study; the drugs were purchased. No one who is not an author contributed to the manuscript. The first, fourth, and last authors vouch for the accuracy and completeness of the reported data and the fidelity of the study to the protocol.
STAGING
All patients underwent pretreatment staging. This included a history taking; physical examination; pulmonary-function tests, routine hematologic and biochemical tests; upper gastrointestinal endoscopy with histologic biopsy and endoscopic ultrasonography; computed tomography of the neck, chest, and upper abdomen; and external ultrasonography of the neck, with fine-needle aspiration of lymph nodes when cancer was suspected. For the final analysis, the available endoscopic reports were centrally reviewed.
TREATMENT
Chemotherapy
On days 1, 8, 15, 22, and 29, carboplatin targeted at an area under the curve of 2 mg per milliliter per minute and paclitaxel at a dose of 50 mg per square meter of body-surface area were administered intravenously. All patients were intravenously premedicated with dexamethasone, clemastine, and ranitidine as well as standard antiemetic agents. The patients were closely monitored for toxic effects of chemotherapy with the use of the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0. 10 
Radiotherapy
A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy each, with 5 fractions administered per week, starting on the first day of the first chemotherapy cycle. All patients were treated by means of external-beam radiation. A detailed description of the methods of administration of chemotherapy and radiotherapy can be found in Appendix 1 in the Supplementary Appendix, available at NEJM.org.
Surgery
Patients in the chemoradiotherapy-surgery group underwent surgery as soon as possible after completion of chemoradiotherapy (preferably, within 4 to 6 weeks), and patients in the surgery group were treated as soon as possible after randomization. A transthoracic approach with two-field lymph-node dissection was performed for tumors extending proximally to the tracheal bifurcation. For tumors involving the esophagogastric junction, a transhiatal resection was preferred. Peritruncal dissection was carried out with both approaches. For all other tumors, the approach depended on the characteristics of the patient and on local preferences. Gastric-tube reconstruction with a cervical anastomosis was the preferred technique for restoring the continuity of the digestive tract.
PATHOLOGICAL ANALYSIS
Reports on pathological examination had to describe the tumor type and extension, lymph nodes, and resection margins. In the absence of macroscopic tumor, any abnormal-appearing tissue was paraffin-embedded in total in order to make an adequate assessment for the presence of residual tumor and the effects of therapy.
To grade the response to therapy, we classified the degree of histomorphologic regression into four categories as follows: grade 1, no evidence of vital residual tumor cells (pathological complete response); grade 2, less than 10% vital residual tumor cells; grade 3, 10 to 50%; and grade 4, more than 50%. 11, 12 If a vital tumor was present at 1 mm or less from the proximal, distal, or circumferential resection margin, it was considered to be microscopically positive (R1).
FOLLOW-UP
During the first year after treatment was completed, patients were seen every 3 months. In the second year, follow-up took place every 6 months, and then at the end of each year until 5 years after treatment. Late toxic effects, disease recurrence, and death were documented. Recurrences were scored at the moment of the first recurrence. During follow-up, diagnostic investigations were performed only when recurrence was suspected.
STATISTICAL ANALYSIS
We calculated that 175 patients were needed in each group in order to detect a difference in median overall survival of 22 months in the chemoradiotherapy-surgery group versus 16 Of the 368 patients who underwent randomization, 178 in the chemoradiotherapy-surgery group and 188 in the surgery group were included in the intention-to-treat analysis. A resection was not possible in 7 patients in the chemoradiotherapy-surgery group and in 25 in the surgery group because the primary tumor or lymph nodes were identified as unresectable during surgery. EGJ denotes esophagogastric junction.
The according to computer-generated randomization lists for each stratum, with random block sizes of 4 or 6. Data were analyzed according to the intentionto-treat principle. The primary end point was overall survival. All other described outcomes were secondary end points. No post hoc analyses were performed. Survival was calculated from Interquartile range 3-6 3-6
Tumor location -no. (%) †
Esophagus
Proximal third 4 (2) 4 (2) Middle third 25 (14) 24 (13) Distal third 104 (58) 107 (57) Esophagogastric junction 39 (22) 49 ( the date of randomization until death. All data collected through December 2010 were included in the analysis, which guaranteed a potential minimal follow-up of 2 years. The Kaplan-Meier method was used to estimate survival, with the log-rank test to determine significance. A Cox proportional-hazards model was used to estimate the treatment effect with adjustment for prognostic factors for survival. Moreover, Cox models were used to identify possible interactions in treatment effect between subgroups, both with and without adjustment for prognostic factors. Subgroups were predefined according to sex, histologic subtype of tumor, clinical N stage, and WHO performance score. Statistical analysis was performed with the use of SPSS software, version 17.0 (SPSS).
R ESULTS
CHARACTERISTICS OF THE PATIENTS
From March 2004 through December 2008, we enrolled 368 patients in the study, of whom 180 were randomly assigned to the chemoradiotherapy-surgery group, and 188 to the surgery group. Two patients who were randomly assigned to the chemoradiotherapy-surgery group withdrew consent and were not included in the analysis (Fig. 1) .
Prognostic factors were well balanced between the two treatment groups (Table 1) . In both groups, the median age was 60 years; 134 of 178 patients (75%) in the chemoradiotherapysurgery group were men, as compared with 152 of 188 patients (81%) in the surgery group. Most patients (275 of 366 [75%]) had an adenocarci- 
DELIVERY AND TOXIC EFFECTS OF CHEMORADIOTHERAPY
Seven patients (4%) in the chemoradiotherapysurgery group did not receive any chemoradiotherapy: 5 because of disease progression before commencing therapy and 2 because they declined the therapy. A total of 162 patients (91%) received the full treatment regimen of five cycles of chemoradiotherapy, and 164 (92%) received the full dose of radiotherapy. Two patients (1%) received a higher dose of radiotherapy (45.0 and 54.0 Gy, respectively). The most common reason for not completing all chemotherapy cycles was a low platelet count. In 12 of 171 patients (7%) who received treatment in the chemoradiotherapy-surgery group, grade 3 hematologic toxic effects were observed; a grade 4 hematologic toxic effect and neutropenic fever developed in 1 patient. One patient died while awaiting surgery after chemoradiotherapy, probably owing to a perforation of the esophagus, accompanied by major hemorrhage in the absence of thrombocytopenia. All other major nonhematologic toxic effects of grade 3 or higher occurred in less than 13% of patients in this group. All serious adverse events that occurred during treatment are summarized in Table 2 .
SURGERY
In the chemoradiotherapy-surgery group, 168 patients (94%) underwent surgery, as compared with 186 (99%) in the surgery group (P = 0.01).
Reasons for not undergoing surgery were the patient's decision (2 patients in the chemoradiotherapy-surgery group), disease progression during treatment (7 in the chemoradiotherapy-surgery group and 1 in the surgery group), diagnosis of a second cancer before surgery (1 in the surgery group), and death before surgery due to toxic effects of chemoradiotherapy (1) . No patients were considered medically unfit for surgery. The median time between randomization and surgery was 97 days in the chemoradiotherapysurgery group and 24 days in the surgery group. The median time between the end of chemoradiotherapy and surgery was 6.6 weeks (interquartile range, 5.7 to 7.9). In 7 of 168 patients (4%) in the chemoradiotherapy-surgery group, a resection was not possible because the primary tumor or lymph nodes were identified during surgery as unresectable, as compared with 25 of 186 patients (13%) in the surgery group (P = 0.002).
Postoperative complications are summarized in Table 2 . No significant differences in the occurrence of complications were found between the two treatment groups. Six of 168 patients (4%) in the chemoradiotherapy-surgery group died in the hospital, as did 8 of 186 (4%) in the surgery group (P = 0.70). Four patients (2%) in the chemoradiotherapy-surgery group died within 30 days after surgery, as compared with 5 (3%) in the surgery group (P = 0.85).
PATHOLOGICAL ASSESSMENT
An R0 resection was achieved in 148 of 161 patients (92%) in the chemoradiotherapy-surgery group, as compared with 111 of 161 (69%) in the surgery group (P<0.001). A pathological complete response (ypT0N0; y denotes underwent neoadjuvant chemoradiotherapy, and p denotes by pathological assessment) was seen in the resection specimens from 47 patients (29%) in the chemoradiotherapy-surgery group. A pathological complete response was observed in 28 of 121 patients with adenocarcinoma (23%) versus 18 of 37 with squamous-cell carcinoma (49%) (P = 0.008). A median of 15 lymph nodes were resected in patients in the chemoradiotherapy-surgery group, as compared with 18 in patients in the surgery group (P = 0.77). One or more positive lymph nodes in the resection specimen were found in 50 patients (31%) in the chemoradiotherapy-surgery group, as compared with 120 patients (75%) in the surgery group (P<0.001). The pathological findings in all resection specimens are summarized in Appendix 2 in the Supplementary Appendix.
SURVIVAL
For surviving patients, the median follow-up was 45.4 months (range, 25.5 to 80.9). Of the 61 patients in the chemoradiotherapy-surgery group who underwent resection and died after having been discharged, 52 (85%) died from recurrent cancer and 9 (15%) from other causes (2 from sepsis, 2 from cardiac failure, 2 from respiratory insufficiency, 1 from kidney failure, 1 from a second primary tumor, and 1 after reconstructive surgery for a persistent postoperative neo-esophagotracheal fistula). Of the 83 patients in the surgery group who underwent resection and died after having been discharged, 78 (94%) died from recurrent cancer, 4 (5%) from other causes (2 from cardiac failure, 1 from respiratory failure, and 1 from a thromboembolic event), and 1 from an unknown cause (P = 0.14). The median disease-free survival for patients who underwent resection was not reached in the chemoradiotherapy-surgery group and was 24.2 months in the surgery group (hazard ratio, 0.498; 95% confidence interval [CI], 0.357 to 0.693; P<0.001).
An intention-to-treat analysis that included all patients showed a median overall survival of 49.4 months in the chemoradiotherapy-surgery group versus 24.0 months in the surgery group (P = 0.003 by the log-rank test; hazard ratio, 0.657; 95% CI, 0.495 to 0.871) (Fig. 2A) . The respective overall survival rates at 1, 2, 3, and 5 years were 82%, 67%, 58%, and 47% in the chemoradiotherapy-surgery group, as compared with 70%, 50%, 44%, and 34% in the surgery group. Adjustment for baseline prognostic factors led to a similar effect estimate (hazard ratio, 0.665; 95% CI, 0.500 to 0.884).
Separate curves for overall survival according to histologic subtype (i.e., adenocarcinoma or squamous-cell carcinoma) are shown in Figure 2B. The benefit of neoadjuvant chemoradiotherapy on survival was consistent across subgroups, without any significant interaction identified.
Hazard ratios for the subgroup effects, with and without adjustment for baseline covariates, are shown in Figure 3 .
DISCUSSION
This large, randomized trial of neoadjuvant chemoradiotherapy in patients with esophageal or esophagogastric-junction cancer showed significantly better overall and disease-free survival among patients who received a chemoradiotherapy regimen based on carboplatin and paclitaxel, followed by surgery, as compared with those treated with surgery alone. The chemoradiotherapy was associated with a low frequency of high-grade toxic effects and could be given as an outpatient treatment. The preoperative treatment did not result in higher postoperative morbidity or early mortality in this group, as compared with the surgery group. Patients treated with neoadjuvant chemoradiotherapy followed by surgery had a 34% lower risk of death during follow-up (hazard ratio, 0.657).
The chemoradiotherapy regimen was designed on the basis of our experience in a previous phase 2 study, 7 which used the same dosages of radiotherapy and chemotherapy. In that study, it was possible to administer this regimen on an outpatient basis, and all the patients had resection margins that were microscopically negative. On the basis of these results, an alteration of the chemoradiotherapy regimen was not thought to be necessary.
The present study was designed to detect a difference in median survival of 6 months in favor of the combined regimen of chemoradiotherapy and surgery, as compared with surgery alone (22 months vs. 16 months). The observed survival in both groups was superior to the anticipated survival and to that reported in earlier randomized trials. 6, [13] [14] [15] [16] [17] In line with the results of other studies, the survival of patients treated with surgery alone has improved, 18, 19 probably owing to ongoing improvements in surgical techniques, patient selection, and staging methods over the years. The difference in overall survival in the present study is not due to poor survival in the surgery group but can clearly be attributed to improved survival in the chemoradiotherapysurgery group. In the chemoradiotherapy-surgery group, 94% of patients underwent surgery, and 90% of tumors could be resected. In the surgery group, 99% of patients underwent surgery, and 86% underwent resection. These percentages indicate that the preoperative chemoradiotherapy did not significantly change the individual chance of undergoing a resection. 14, 15, 17 Postoperative complication rates, although similar between groups, were higher than expected and higher than reported in other studies. 20 We could not find a plausible explanation for this finding, other than the fact that all postoperative events were meticulously recorded. This relatively high incidence of postoperative events in both treatment groups did not result in an increased postoperative mortality, which was low and similar in the two groups.
Complete remission in both the primary tumor and the lymph nodes (ypT0N0) was the best possible pathological outcome of chemoradiotherapy. The observed percentage of patients with a pathological complete response (29%) is in line with the reported percentages in other phase 2 and phase 3 studies. 7, 13, 14, 18, 21 The substantial downstaging as a result of chemoradiotherapy is also reflected in the significantly higher percentage of R0 resections in the chemoradiotherapy-surgery group.
Despite the higher rate of pathological complete response among patients with squamouscell carcinoma, as compared with those with adenocarcinoma, histologic tumor type was not a prognostic factor for survival. That is, patients with adenocarcinoma and patients with squamous-cell carcinoma both benefited from neoadjuvant chemoradiotherapy.
Whether esophageal and esophagogastricjunction tumors should be treated with preop- In the POET trial, only patients with esophagogastric-junction tumors were included and randomly assigned to preoperative chemotherapy or chemoradiotherapy. 24 In that study, there was a nonsignificant trend in favor of preoperative chemoradiotherapy. Because a substantial percentage of patients in the chemoradiotherapysurgery group in the present study (22%) had an esophagogastric-junction tumor, we favor preoperative chemoradiotherapy for such patients, as was also suggested by the POET study, especially because of the limited toxic effects that were observed with this treatment regimen. In conclusion, preoperative chemoradiotherapy (five courses of carboplatin and paclitaxel, with 41.4 Gy of concurrent radiotherapy) is safe and leads to a significant increase in overall survival among patients with adenocarcinoma or squamous-cell carcinoma of the esophagus or esophagogastric junction.
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